2021 ASCO Virtual Meeting: Leukemia TALK

home / the-talk / 2021-asco-virtual-meeting-leukemia-talk

Expert perspectives on trial designs, study populations, safety/efficacy results, and practical implications from the 2021 ASCO (American Society of Clinical Oncology) and EHA (The European Hematology Association).

Funding from Amgen Oncology and Takeda Oncology/Content Developed Independently by OncLive

EP. 1: OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment

By Jorge Cortes, MD, Georgia Cancer Center
Robin Foa, MD, Sapienza University

July 8th 2021

Jorge Cortes, MD, reviews the results of the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib.

EP. 2: Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

By Jorge Cortes, MD, Georgia Cancer Center
Robin Foa, MD, Sapienza University

July 8th 2021

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

EP. 3: GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

By Jorge E. Cortes, MD, MD Anderson Cancer Center
Robin Foa, MD, Sapienza University

July 8th 2021

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.

EP. 4: GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

By Jorge Cortes, MD, Georgia Cancer Center
Robin Foa, MD, Sapienza University

July 8th 2021

Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.

EP. 5: MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

By Jorge Cortes, MD, Georgia Cancer Center
Robin Foa, MD, Sapienza University

July 8th 2021

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).